Table 2 Characteristics [mean (SD) or n (%)] of the study population (n = 1934)
From: Coronary heart disease and mortality following a breast cancer diagnosis
|  | Total (n = 1934) | CHD(n = 664) | Death (n = 374) |
|---|---|---|---|
Age (years) | |||
 Mean (SD) | 58.5 (12.9) | 62.9 (13.1) | 61.4 (13.9) |
 20–40 | 135 (7.0) | 23 (3.5) | 23 (6.1) |
  > 40–60 | 975 (50.4) | 260 (39.2) | 159 (42.5) |
  > 60–100 | 824 (42.6) | 381 (57.4) | 192 (51.3) |
Race | |||
 Black | 435 (22.5) | 209 (31.5) | 126 (33.7) |
 Non-black | 1419 (73.4) | 433 (65.2) | 226 (60.4) |
 Unknown | 80 (4.1) | 22 (3.3) | 22 (5.9) |
BMI (kg/m2) | 21.9 (13.6) | 29.3 (8.3) | 28.1 (10.1) |
Systolic blood pressure (SBP, mmHg) | 125.4 (20.7) | 128.4 (22.0) | 126.0 (20.7) |
Diastolic blood pressure (DBP, mmHg) | 69.8 (11.2) | 69.8 (11.6) | 69.4 (11.4) |
Fasting glucose (mg/dL) | 109.3 (33.3) | 129.9 (53.6) | 127.6 (58.3) |
Hemoglobin A1c (%) | 6.94 (1.9) | 7.05 (1.8) | 7.45 (2.3) |
Total cholesterol (mg/dL) | 186.6 (50.3) | 181.6 (46.6) | 178.9 (61.0) |
Current smoking | 66 (3.4) | 51 (7.7) | 18 (4.8) |
Taking antihypercholesterolemia medication | 367 (19.0) | 267 (40.2) | 88 (23.5) |
Taking antihypertensive medication | 461 (23.8) | 386 (58.1) | 215 (57.5) |
Taking diabetic medications | 346 (17.9) | 238 (35.8) | 138 (36.9) |
Classes of potentially cardiotoxic cancer treatmentsa | |||
Total patients (%) receiving treatments | 341 (17.6) | 201 (30.3) | 128 (34.2) |
 Anthracyclines | 6 (1.8) | 4 (2.0) | 3 (2.3) |
 Hormone therapy | 87 (25.5) | 51 (25.4) | 28 (21.9) |
 Aromatase inhibitors | 158 (46.3) | 97 (48.3) | 44 (34.3) |
 Monoclonal antibodies | 7 (2.1) | 3 (1.5) | 2 (1.6) |
 Antimicrotubule agents | 15 (4.4) | 9 (4.5) | 9 (7.0) |
 Alkylating agents | 21 (6.2) | 12 (6.0) | 12 (9.4) |
 Antimetabolites | 37 (10.9) | 20 (10.0) | 27 (21.1) |
 Other | 10 (2.9) | 5 (2.5) | 3 (2.3) |